Gozellix

Telix’s Gozellix receives Transitional Pass-Through (TPT) status from CMS, enabling separate reimbursement under HOPPS and eliminating 20% patient coinsurance starting October 1, 2025. Gozellix offers longer shelf life, broader distribution, and flexible production, improving PSMA-PET imaging accessibility for prostate cancer. While it advances diagnostics, potential risks include image misinterpretation, radiation exposure, and variable performance based on PSA levels. TPT status may significantly boost Telix’s market position.